OverviewSuggest Edit

EastGate Biotech produces and distributes innovative and healthy nutraceuticals that are based on natural therapies and absorbed naturally by the body. EastGate Biotech develops products in which the active components are incorporated into vehicles containing nano-sized delivery vectors, including: oil droplets (nanoemulsions), polymeric particles (nanoparticles), and the combination of polymers and lipids with surfactants (hybrid nanoparticles, nanocapsules, mixed micelles). 

TypePublic
Founded1999
HQToronto, CA
Websiteeastgatebiotech.com

Latest Updates

Employees (est.) (Dec 2016)2
Revenue (FY, 2015)$132 K
Share Price (Jul 2020)$0
Cybersecurity ratingAMore

Key People/Management at EastGate Biotech

Anna Gluskin

Anna Gluskin

CEO
Rose Perri

Rose Perri

President
Show more

EastGate Biotech Office Locations

EastGate Biotech has an office in Toronto
Show all (1)

EastGate Biotech Financials and Metrics

EastGate Biotech Revenue

EastGate Biotech's revenue was reported to be $132.03 k in FY, 2015
USD

Revenue (Q3, 2017)

23.1k

Gross profit (Q3, 2017)

(69.2k)

Gross profit margin (Q3, 2017), %

(299.1%)

Net income (Q3, 2017)

(1.6m)

EBIT (Q3, 2017)

(1.7m)

Market capitalization (9-Jul-2020)

6.2m

Closing stock price (9-Jul-2020)

0.0

Cash (30-Sept-2017)

4.9k

EV

6.9m
EastGate Biotech's current market capitalization is $6.2 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

132.0k

Cost of goods sold

19.2k

Gross profit

112.8k

Gross profit Margin, %

85%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

58.5k73.2k90.8k1.7k114.5k23.1k

Cost of goods sold

8.4k11.1k14.0k56.9k92.3k

Gross profit

50.1k62.1k76.8k57.6k(69.2k)

Gross profit Margin, %

86%85%85%50%(299%)
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

100.0k458.0286.5k19.2k

Prepaid Expenses

4.5k

Current Assets

104.5k458.0339.7k113.5k

PP&E

71.3k143.2k184.4k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

10.9k1.8k26.4k784.0k375.3k6.2k28.9k10.8k72.5k9.3k78.6k4.9k

Accounts Receivable

36.0k868.3k28.7k

Prepaid Expenses

4.5k21.7k

Inventories

112.9k
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(29.9k)(622.8k)(1.7m)(4.9m)(4.3m)(3.0m)

Depreciation and Amortization

14.5k27.9k44.2k

Accounts Payable

11.4k216.8k192.2k47.4k100.0k18.9k

Cash From Operating Activities

(407.7k)(1.2m)(568.4k)(389.5k)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(5.5k)(5.8k)(7.2k)(224.6k)(165.7k)(166.5k)(392.0k)(636.2k)(2.9m)(3.9m)(1.8m)(2.6m)(3.5m)(1.5m)(1.3m)(2.0m)(952.1k)(1.7m)(3.2m)

Depreciation and Amortization

9.6k18.7k9.3k18.6k30.7k27.1k40.7k73.7k

Accounts Payable

3.3k44.3k117.2k189.8k(83.0k)(92.3k)7.1k49.2k67.5k(15.1k)2.0k(7.4k)111.2k182.6k733.7k

Cash From Operating Activities

(74.8k)(74.2k)(231.8k)(412.9k)(810.9k)(1.2m)(266.0k)(430.1k)(550.1k)(103.5k)(113.7k)(221.1k)(121.5k)(252.5k)(1.6m)
Show all financial metrics

EastGate Biotech Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

EastGate Biotech Online and Social Media Presence

Embed Graph

EastGate Biotech News and Updates

EastGate Biotech Pakistan Expands its Collaboration in Advancing the Development of a New Vaccine Against COVID-19

Joint Venture Collaboration to also pursue antibiotic products to create a pipeline to fight various new strains of flu illnessesWest Caldwell, NJ and Toronto, Canada - (NewMediaWire) - February 18, 2020 - EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company that focuses on innova…

EastGate Biotech Pakistan Receives International Marketing Rights of Anaferon an Approved Coronavirus Treatment to Potentially Combat the Wuhan Coronavirus

West Caldwell, NJ and Toronto, Canada - (NewMediaWire) - January 30, 2020 - EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company, that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today that …

EastGate Biotech Provides Summary of 2019 Corporate and Development Highlights

WEST CALDWELL, NJ and TORONTO, ON, Dec. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, today provide…

EastGate Biotech Expands Pipeline to Alzheimer’s Disease Using its Alternative Insulin Delivery Platform

WEST CALDWELL, NJ and TORONTO, ON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced to…

EastGate Biotech Announces Expansion and Restructuring of Joint Venture with its Partner in Pakistan

Key products to be tested, registered and marketed include Insugin for diabetes application, alternative insulin for Alzheimer’s application, and Blood Plasma Derived Products, Human Serum Albumin 20% West Caldwell, NJ and Toronto, Canada - (NewMediaWire) - October 09, 2019 - EastGate Biotech C…

EastGate Biotech Receives Regulatory Approval to Initiate a Phase III 90-day Clinical Trial on Insugin, Its Liquid Insulin Mouth Rinse Solution

The Marketing Application Approval in Pakistan will follow subject to completion of the Phase III clinical study that will include up to 200 Type 2 patients West Caldwell, NJ and Toronto, Canada - (NewMediaWire) - September 25, 2019 - EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical c…
Show more

EastGate Biotech Blogs

Link to interview with Ms. Anna Gluskin, CEO, Eastgate Biotech Corp. on Wall Street Analyzer

Link to the interview of Eastgate's CEO Ms. Anna Gluskin....

Eastgate BioTech Corp (OTCBB: ETBI) Interview with CEO Anna Gluskin

Eastgate BioTech Corp (OTCBB: ETBI) Interview with CEO Anna Gluskin...

https://upticknewswire.com/interview-ceo-anna-gluskin-of-eastgate-biotech-corp-otc-etbi/

Interview: CEO Anna Gluskin of Eastgate Biotech Corp. (OTC: ETBI)...

Eastgate Biotech Signs Strategic Alliance Agreement with MJ Biopharm for Insulin API Supply

Alliance with MJ Biopharm of Mumbai, India positions the company to further its plans for SEA countries for its liquid insulin mouth rinse...

EastGate Biotech Attends Arab Health Conference Seeking Additional Joint Venture Partnerships

EastGate Biotech to Showcase Insulin Products at the Dubai World Trade Centre...

EastGate Biotech Appoints World Renown Diabetes Key Opinion Leader Dr Lalit Upadhyay for Upcoming Initiatives

EastGate Biotech Appoints World Renown Diabetes Key Opinion Leader Dr. Lalit Upadhyay for Upcoming Initiatives...
Show more

EastGate Biotech Frequently Asked Questions

  • When was EastGate Biotech founded?

    EastGate Biotech was founded in 1999.

  • Who are EastGate Biotech key executives?

    EastGate Biotech's key executives are Anna Gluskin and Rose Perri.

  • How many employees does EastGate Biotech have?

    EastGate Biotech has 2 employees.

  • Who are EastGate Biotech competitors?

    Competitors of EastGate Biotech include Baze, Olympian Labs and American BioSciences.

  • Where are EastGate Biotech offices?

    EastGate Biotech has an office in Toronto.

  • How many offices does EastGate Biotech have?

    EastGate Biotech has 1 office.